Guess which small cap ASX share could rise 100%+

A leading broker is tipping big returns from this speculative stock.

| More on:
A person with a round-mouthed expression clutches a device screen and looks shocked and surprised.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Immutep Ltd (ASX: IMM) shares ended the week on a disappointing note.

The small cap ASX biotechnology share fell 3% to finish the session at 33 cents.

But its shares may not be trading at those levels for long if one leading broker is to be believed.

What is being said about this small cap ASX share?

Analysts at Bell Potter have been looking over a recent data update and were pleased with what they saw. Commenting on the INSIGHT-003 trial, the broker said:

IMM have provided a data update from the Phase 1 trial called INSIGHT-003 evaluating Efti in combination with Keytruda + chemo in first-line non-small cell lung cancer (1L NSCLC) patients. We consider the data to be a strong update and provides further support heading into the pivotal Phase 3 trial starting in the next few months using the same treatment regimen in a similar patient population.

Bell Potter highlights that the median survival data was strong and was a key highlight from the release. It adds:

A key highlight was the 32.9 months median survival for the first 21 patients, roughly 11 months longer than the 22.0 months observed for a similar patient group in the historical Keytruda + chemo Phase 3 trial (KEYNOTE-189). Additionally, the first 21 subjects showed favourable outcomes relative to the historical phase 3 trial in terms of (1) median progression-free survival (mPFS) of 12.7m vs. 9.0 months; and (2) 24- month survival rate of 81% vs 46%.

Big potential returns

According to the note, the broker has held firm with its speculative buy rating and 70 cents price target on the small cap ASX share.

This implies massive potential upside of 111% for investors over the next 12 months.

To put that into context, a $500 investment would be worth approximately $1,050 by this time next year if Bell Potter is on the money with its recommendation.

The broker acknowledges that there's still a lot of work to be done, but that the early signs are positive. It concludes:

While INSIGHT-003 is a relatively small trial lacking a head-to-head control arm, the data so far looks promising and provides added confidence in the upcoming Phase 3 trial (n=750) utilising the same treatment regimen. First-line NSCLC is one of the most lucrative oncology indications, and while the Ph3 will be a multi-year trial, there are futility and interim readout events along the way to maintain interest.

There are no changes to our forecasts after this data update. We maintain our BUY (spec.) recommendation and $0.70 valuation. Upcoming readouts in the next 12 months include: (1) further head & neck Ph2 data (Cohort B update on 12-Dec-2024, Cohort A survival data 2025); (2) Ph1 results with autoimmune drug candidate in healthy volunteers; and (3) Ph2 breast cancer results using the 90mg dose (having potential relevance for the Ph3 dose in 1L NSCLC).

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Small Cap Shares

Three analysts look at tech options on a wall screen
Technology Shares

Why did this small-cap ASX tech stock just explode 39%?

Investors are piling into the ASX tech stock on Wednesday. But why?

Read more »

Siblings jumping on a trampoline.
Broker Notes

3 ASX small-cap stocks to buy for 2025: brokers

Here are 3 ASX small-cap shares capturing the attention of professional brokers this week.

Read more »

A man sits in a chair hunched over a laptop and covered head to toe in frozen icicles to represent Envirosuite's trading halt
Small Cap Shares

ASX small-cap stock halted amid global semiconductor deal

Investors are awaiting details of a capital raise.

Read more »

A young man sitting at an outside table uses a card to pay for his online shopping.
Small Cap Shares

Why I think this ASX small-cap share is a bargain at $1.20

This retail stock could be a bargain buy right now.

Read more »

a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
Small Cap Shares

These small cap ASX shares could rise 20% to 50%

These shares could be destined to deliver big returns over the next 12 months according to brokers.

Read more »

three children wearing superhero costumes, complete with masks, pose with hands on hips wearing capes and sneakers on a running track.
Small Cap Shares

3 ASX small-cap shares to buy now: brokers

The ASX Small Ordinaries Index has lifted 6.5% over the past six months alone.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Small Cap Shares

This ASX small cap stock just rocketed 40%! Here's why

Let's see what is getting investors excited this morning.

Read more »

Kid putting a coin in a piggy bank.
Small Cap Shares

Down 72% form its highs, why this ASX small-cap stock is now 'a bargain'

Everyone likes a bargain.

Read more »